G,, A. Et Al. 2015. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment. EUR J SUR ONCOL .

G,, A., ORDU, Ç., D,, S., F,, Ç., ERDOĞAN, Z., AĞACAYAK, F., ... S,, İ.(2015). Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment . EUR J SUR ONCOL

G,, ALÇO Et Al. "Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment," EUR J SUR ONCOL, 2015

G,, ALÇO Et Al. "Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment." EUR J SUR ONCOL , 2015

G,, A. Et Al. (2015) . "Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment." EUR J SUR ONCOL .

@conferencepaper{conferencepaper, author={ALÇO G, Et Al. }, title={Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment}, congress name={EUR J SUR ONCOL}, city={}, country={}, year={2015}}